Correlation analysis of cytokines level and peripheral blood T lymphocyte subsets in systemic vascular inflammatory disease
Cytokines level and peripheral blood T lymphocyte subsets in systemic vascular inflammatory disease
Abstract
Objective: To measure the levels of T-cell subsets and cytokines in the peripheral blood of patients with systemic vascular inflammatory disease and to analyze the influence of different clinical characteristics of systemic vascular inflammatory disease patients on the levels of T-cell subsets and cytokines in the peripheral blood.
Methods: The case group consisted of 80 systemic vascular inflammatory disease patients who were diagnosed and treated at our hospital between January 2021 and December 2024. Forty healthy volunteers were selected from our hospital's health assessment center to form the control group. The expression of helper T-cell (Th)1, Th17 and regulatory T-cell (Treg) subsets in the peripheral circulation was determined via flow cytometry. The levels of the cytokines interleukin and interferon-γ (IFN-γ) in the serum were measured via enzyme-linked immunosorbent assay (ELISA). levels of tumor necrosis factor-α (TNF-α), IL-4, IL-10, IL-17, and IL-6.
Results: Compared with those in the control group, the expression levels of total T lymphoid subsets and CD8+ T and Th1 cells in systemic vascular inflammatory disease patients were significantly greater, and there was no statistically significant difference in Th, Th17, or Treg cell expression between the groups (P>0.05). However, there were statistically significant differences between the two groups [68.75 (54.23, 80.32)] and [72.10 (62.23, 86.45)], [23.44 (12.89, 33.76)] and [31.46 (20.13, 45.26)], [10.67 (8.23, 12.35)] and [10.26, 17.96 [25.39)], Z = -3.13, -4.54, -3.97 (all P values <0.05). Compared with those in the control group, systemic vascular inflammatory disease patients had significantly higher serum levels of IL-17, IL-6, TNF-α, IL-4, and IFN-γ, whereas their serum levels of IL-10 were significantly lower. The differences were statistically significant (Z = -4.32, -5.01, -8.18, -8.70, -3.48, and -8.30). The P values were all <0.05. Compared with that in patients without related manifestations, IL-6 expression was noticeably higher in systemic vascular inflammatory disease patients with arthritic symptoms and those with active systemic vascular inflammatory disease, and the difference was statistically significant {pg/mL: [3.23 (2.98, 5.35)] compared with [10.51 (6.72, 23.21)], [6.32 (4.79, 8.93)] compared with [9.68 (6.97, 18.73)], Z = 5.47, 8.76, P values < 0.05}. Compared with those in patients without relevant clinical manifestations, the levels of TNF-α in patients with arthritis manifestations, ocular manifestations, digestive tract manifestations and active systemic vascular inflammatory disease were significantly greater, whereas the levels of IFN-γ in systemic vascular inflammatory disease patients with digestive system lesions were significantly greater. The differences were statistically significant {pg/mL: [7.74 (6.89, 10.19)] compared with [39.84 (30.37, 50.61)], [6.12 (5.36, 9.89)] compared with [31.35 (15.71, 30.46)], [6.49 (4.78, 10.21)] compared with [19.89 (14.36, 36.21)]. [5.89 (4.61, 8.96)] than [27.91 (15.32, 37.81)], [6.89 (5.43, 14.86)] than [26.79 (15.41, 31.56)], Z = 7.70, 6.84, 6.94, 9.47, 5.70, P values < 0.05}. However, there was no statistically significant difference in the expression levels of IL-4 and IL-17 between systemic vascular inflammatory disease patients without relevant clinical manifestations and those with relevant clinical manifestations (P>0.05).
Conclusion: Patients with systemic vascular inflammatory disease have an imbalance of T lymphocyte subsets and cytokines, and disease activity and clinical classification may involve an imbalance of T-cell subsets and cytokines.
References
2.Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Behçet's disease uveitis. Prog Retin Eye Res. 2023 Nov;97:101216. doi: 10.1016/j.preteyeres.2023.101216. Epub 2023 Sep 19. PMID: 37734442.
3.Alharthy F, Almaqati AS, Alsulami S, Ahmad A. Behçet's Disease in Saudi Arabia: Clinical and Demographic Characteristics. Cureus. 2023 Feb 11;15(2):e34867. doi: 10.7759/cureus.34867. PMID: 36923194; PMCID: PMC10010633.
4.Bergamo S. The diagnosis of Adamantiades-Behçet disease: Clinical features and diagnostic/classification criteria. Front Med (Lausanne). 2022 Dec 9;9:1098351. doi: 10.3389/fmed.2022.1098351. PMID: 36569165; PMCID: PMC9780472.
5.Bergamo S. The diagnosis of Adamantiades-Behçet disease: Clinical features and diagnostic/classification criteria. Front Med (Lausanne). 2022 Dec 9;9:1098351. doi: 10.3389/fmed.2022.1098351. PMID: 36569165; PMCID: PMC9780472.
6.Ding Y, Hu W, Li L, Guan W, Guan K, He Y, Liu S, Li TF. Clinical features and independent predictors of Behçet's disease associated with myelodysplastic syndrome. Clin Exp Rheumatol. 2023 Sep;41(9):1823-1830. doi: 10.55563/clinexprheumatol/04us5e. Epub 2023 Feb 7. PMID: 36762734.
7.Kidd DP. Neurological involvement by Behçet's syndrome: clinical features, diagnosis, treatment and outcome. Pract Neurol. 2023 Oct;23(5):386-400. doi: 10.1136/pn-2023-003875. Epub 2023 Sep 29. PMID: 37775123.
8.Zhan H, Cheng L, Li Y. Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis. Clin Exp Immunol. 2025 Jan 21;219(1):uxae123. doi: 10.1093/cei/uxae123. PMID: 39774671; PMCID: PMC11755846.
9.Tono T, Kikuchi H, Sawada T, Takeno M, Nagafuchi H, Kirino Y, Tanaka Y, Yamaoka K, Hirohata S. Clinical features of Behçet's disease patients with joint symptoms in Japan: A national multicenter study. Mod Rheumatol. 2022 Oct 15;32(6):1146-1152. doi: 10.1093/mr/roab092. PMID: 34850090.
10.Çakan ZK, Yağız B, Pehlivan Y. Clinical features of Behçet's disease and prediction of the use of biologics in 488 cases: a single tertiary center study. Rheumatol Int. 2023 Nov;43(11):2089-2097. doi: 10.1007/s00296-023-05416-0. Epub 2023 Aug 22. PMID: 37604938.
11.Konak HE, Erden A, Armağan B, Güven SC, Apaydın H, Dağlı PA, Uzun Y, Kaygısız M, Küçükşahin O, Omma A. Effects of breast milk on Behçet's disease clinical features. Turk J Med Sci. 2023 Feb;53(1):121-129. doi: 10.55730/1300-0144.5565. Epub 2023 Feb 22. PMID: 36945965; PMCID: PMC10387996.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Romão VC, Khmelinskii N. Clinical and ultrasonographic features of erythema nodosum in Behçet's disease. Rheumatology (Oxford). 2022 Aug 3;61(8):e254. doi: 10.1093/rheumatology/keac035. PMID: 35048944.
14.Al-Omoush O, AlBarakat MM, Alasmar D, Al-Khalaileh A, Alzoubi A, Tarakhan H, Shakhatreh Z, Hatamleh Z, Abu-Saleh M, Saleh O, Altiti A, A Hazaymeh W, Alshwayyat S, Hanifa H, Hazaimeh E. Clinical and imaging features of parenchymal and nonparenchymal neuro-Behçet's disease: a systematic review of case reports and series. BMC Neurol. 2025 May 26;25(1):225. doi: 10.1186/s12883-025-04250-0. PMID: 40419971; PMCID: PMC12107814.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
16.Lee S, Kang S, Eun Y, Kim H, Lee J, Koh EM, Kim DK, Cha HS. Clinical characteristics and radiographic outcomes of vascular Behçet's disease involving the aorta or its major branches. Clin Rheumatol. 2022 Jun;41(6):1769-1777. doi: 10.1007/s10067-021-06031-9. Epub 2022 Feb 7. PMID: 35128590.
17.Triggianese P, Vitale A, Lopalco G, Mayrink Giardini HA, Ciccia F, Al-Maghlouth I, Ruscitti P, Sfikakis PP, Iannone F, de Brito Antonelli IP, Patrone M, Asfina KN, Di Cola I, Laskari K, Gaggiano C, Tufan A, Sfriso P, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Fotis L, Direskeneli H, Spedicato V, Dagostin MA, Iacono D, Ali HH, Cipriani P, Sota J, Kardasini RC, Bindoli S, Campochiaro C, Navarini L, Gentileschi S, Martín-Nares E, Torres-Ruiz J, Saad MA, Kourtesi K, Alibaz-Oner F, Sevik G, Iagnocco A, Makowska J, Govoni M, Monti S, Maggario MC, La Torre F, Del Giudice E, Hernández- Intern Emerg Med. 2023 Nov;18(8):2231-2243. doi: 10.1007/s11739-023-03408-3. Epub 2023 Oct 12. Erratum in: Intern Emerg Med. 2024 Jan;19(1):255-257. doi: 10.1007/s11739-023-03511-5. PMID: 37828268; PMCID: PMC10635948.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Casares-Marfil D, Esencan D, Alibaz-Oner F, Çefle A, Yazıcı A, Duzgun N, Aşık MA, Özbek S, Cinar M, Alpsoy E, Bilge SY, Kasifoglu T, Saruhan-Direskeneli G, Direskeneli H, Sawalha AH. Clinical trait-specific genetic analysis in Behçet's disease identifies novel loci associated with ocular and neurological involvement. Clin Immunol. 2023 Aug;253:109657. doi: 10.1016/j.clim.2023.109657. Epub 2023 Jun 2. PMID: 37271218; PMCID: PMC10529450.
20.Zhang B, Yang Y, Kuang T, Xu Z, Gong J. Analysis of clinical and imaging features of Behcet's disease-related pulmonary lesions: a series of eight cases. Chin Med J (Engl). 2022 Aug 20;135(16):2011-2013. doi: 10.1097/CM9.0000000000002338. PMID: 36378138; PMCID: PMC9746756.
21.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
22.Muñoz SA, Kostianovsky A, Allievi A, Orden AO. Behçet disease in Latin American countries: A systematic literature review of demographic and clinical features, and HLA-B*51 allele frequency. Reumatol Clin (Engl Ed). 2023 Aug-Sep;19(7):386-391. doi: 10.1016/j.reumae.2022.12.005. PMID: 37661116.
23.Wu YC, Fu YJ, Xia HJ, Zhu J, Huang Y, Jiang ZN. Ileocecal involvement in intestinal Behçet's disease and Crohn's disease: comparison of clinicopathological and immunophenotypic features. J Dig Dis. 2023 Nov;24(11):594-602. doi: 10.1111/1751-2980.13236. Epub 2023 Nov 21. PMID: 37864553.
24.Ding X, Yang J, Han X, Shen YF, Yang K, Shangguan Y, Dong Y, Ye X. Clinical features and novel pathogenic variants of patients with Behçet's disease like trisomy 8. Orphanet J Rare Dis. 2025 Jul 4;20(1):340. doi: 10.1186/s13023-025-03878-y. PMID: 40616106; PMCID: PMC12228353.
25.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
26.Liu Z, Yang C, Bai X, Shen K, Qiao L, Wang Q, Yang H, Qian J. Clinical features and prognosis of patients with gastrointestinal Behçet's disease-like syndrome and myelodysplastic syndrome with and without trisomy 8. Semin Arthritis Rheum. 2022 Aug;55:152039. doi: 10.1016/j.semarthrit.2022.152039. Epub 2022 Jun 3. PMID: 35689913.
27.Gürel Bedir A, Kilic SS. Clinical characteristics and quality of life in children with PFAPA syndrome and Behçet's disease. Rheumatol Adv Pract. 2025 Feb 11;9(1):rkaf015. doi: 10.1093/rap/rkaf015. PMID: 39959133; PMCID: PMC11829805.
28.Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, Naddei R, Di Cola I, Di Muzio C, Berardicurti O, Iacono D, Pantano I, Rozza G, Rossi S, De Stefano L, Balduzzi S, Vitale A, Caso F, Costa L, Prete M, Navarini L, Iagnocco A, Atzeni F, Guggino G, Perosa F, Cantarini L, Frediani B, Montecucco C, Ciccia F, Cipriani P, Gattorno M, Giacomelli R, Ravelli A. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology (Oxford). 2022 Oct 6;61(10):4124-4129. doi: 10.1093/rheumatology/keac027. PMID: 35078234; PMCID: PMC9536787.
29.Yoo JW, Jo SI, Shin DW, Park JW, Kim SE, Lim H, Kang HS, Moon SH, Kim MK, Kim SY, Hwang SW, Soh JS. Clinical Usefulness of Immune Profiling for Differential Diagnosis between Crohn's Disease, Intestinal Tuberculosis, and Behcet's Disease. Diagnostics (Basel). 2023 Sep 11;13(18):2904. doi: 10.3390/diagnostics13182904. PMID: 37761270; PMCID: PMC10529363.
30.Murakami K, Arai J, Ihara S, Tsuchida Y, Shoda H, Tsuboi M, Kurokawa K, Shiomi C, Suzuki N, Hayakawa Y, Fujio K, Fujishiro M. Upper gastrointestinal involvement of Behçet's disease in Japan: endoscopic findings and clinical features. J Gastroenterol Hepatol. 2024 Apr;39(4):708-715. doi: 10.1111/jgh.16479. Epub 2024 Jan 7. PMID: 38185774.
31.Makkawi S, Aljafari D, Alsharif R, Maaddawi H, Alwagdani A, Aljumah T, Alghweinem Z, Alshehri S, Khojah O, Halawani A, Ahmed Adas R, Abulaban A, Al Malik Y. The clinical and radiological features and prevalence of Neuro-Behçet's Disease: A retrospective cohort multicenter study in Saudi Arabia. Mult Scler Relat Disord. 2024 May;85:105558. doi: 10.1016/j.msard.2024.105558. Epub 2024 Mar 20. PMID: 38569381.
32.Zhou J, Zhang D, Wang Z, Hou Y, Liu J, Zeng X, Wang Y, Zheng W. The clinical features, image findings and risk factors for vena cava syndrome in Behçet's syndrome. Clin Exp Rheumatol. 2022 Sep;40(8):1526-1534. doi: 10.55563/clinexprheumatol/r6her6. Epub 2022 Jul 11. PMID: 35819814.
33.Li Y, Xiong Z, Jiang Y, Shen Y, Hu X, Hu D, Li Z. Enhancing the Differentiation between Intestinal Behçet's Disease and Crohn's Disease through Quantitative Computed Tomography Analysis. Bioengineering (Basel). 2023 Oct 17;10(10):1211. doi: 10.3390/bioengineering10101211. PMID: 37892941; PMCID: PMC10604024.
34.Prtenjača L, Mayer M, Karanović B, Rukavina K, Bakula M, Padjen I, Šćepović-Ljucović M, Tomičević LS, Anić B, Barešić M. Demographics and clinical manifestations in patients with Behçet's disease: a retrospective observational study from a nonendemic country. Rheumatol Int. 2025 Apr 15;45(5):102. doi: 10.1007/s00296-025-05855-x. PMID: 40232346.
35.Kaymaz S, Aydın D, Uğur K, Çobankara V, Tan S. Expression Levels and Clinical Values of miR-195, miR-424, miR-10b, miR-103a-3p, and miR-542-3p in Vasculo-Behçet's Disease. Mediterr J Rheumatol. 2023 Sep 7;35(2):255-262. doi: 10.31138/mjr.030623.elc. PMID: 39211027; PMCID: PMC11350416.
36.Elidrissi EH, Elaissat EM, Assoufi N, Tbouda M. Association of Sweet's Syndrome and Behçet's Disease: Is It Possible? A Case Report. Eur J Case Rep Intern Med. 2023 Sep 19;10(10):004073. doi: 10.12890/2023_004073. PMID: 37789984; PMCID: PMC10545150.
37.Park Y, Ahn JB, Kim DH, Park IS, Son M, Kim JH, Ma HW, Kim SW, Cheon JH. Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet's Disease. Int J Mol Sci. 2024 Jun 18;25(12):6697. doi: 10.3390/ijms25126697. PMID: 38928402; PMCID: PMC11203907.
Copyright (c) 2025 Zhonghan Lin, Xuanyang Dong, Junye Chen, Biao Li

This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
